OVERSEA CHINESE BANKING Corp Ltd Has $1.39 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OVERSEA CHINESE BANKING Corp Ltd boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 286.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,319 shares of the biopharmaceutical company's stock after buying an additional 978 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd's holdings in Regeneron Pharmaceuticals were worth $1,387,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of REGN. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company's stock worth $8,595,268,000 after purchasing an additional 91,956 shares during the last quarter. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock worth $567,864,000 after purchasing an additional 59,769 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Leerink Partnrs cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $1,107.25.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.48% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $16.67 during trading hours on Wednesday, reaching $804.33. 589,526 shares of the company's stock were exchanged, compared to its average volume of 524,091. The firm has a fifty day moving average of $1,007.57 and a 200-day moving average of $1,037.30. Regeneron Pharmaceuticals, Inc. has a one year low of $784.96 and a one year high of $1,211.20. The stock has a market cap of $88.39 billion, a PE ratio of 20.09, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.